A single-pill combination of amlodipine besylate and atorvastatin calcium (update).
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering agent, and atorvastatin calcium, a statin with lipid-lowering antiatherosclerotic properties. Amlodipine and atorva...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2007
|
| _version_ | 1797059050390683648 |
|---|---|
| author | Blank, R Hobbs, F Zamorano, J Girerd, X |
| author_facet | Blank, R Hobbs, F Zamorano, J Girerd, X |
| author_sort | Blank, R |
| collection | OXFORD |
| description | This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering agent, and atorvastatin calcium, a statin with lipid-lowering antiatherosclerotic properties. Amlodipine and atorvastatin have been demonstrated in numerous clinical trials to be highly effective in lowering blood pressure and low-density lipoprotein cholesterol. Furthermore, both amlodipine and atorvastatin have been demonstrated to reduce cardiovascular events in a broad range of patients' in hypertensive patients with three concomitant cardiovascular risk factors but normal to mildly elevated cholesterol levels, amlodipine combined with atorvastatin demonstrated a reduction in cardiovascular events. The amlodipine/atorvastatin single pill has been shown to improve patients; achievement of national-guideline-recommended blood pressure and lipid target levels and exhibits a safety profile consistent with its parent compounds. The combination pill is now available in parts of Europe in formulations containing either 5 or 10 mg amlodipine and 10 mg atorvastatin. Amlodipine combined with atorvastatin has been demonstrated to reduce cardiovascular events in hypertensive patients at high cardiovascular risk, and the single-pill formulation has the potential to improve adherence and decrease prescription costs. These potential benefits are associated with important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events. |
| first_indexed | 2024-03-06T19:58:46Z |
| format | Journal article |
| id | oxford-uuid:268bdfe9-ba51-4f27-bd16-dd127271693c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:58:46Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:268bdfe9-ba51-4f27-bd16-dd127271693c2022-03-26T12:01:37ZA single-pill combination of amlodipine besylate and atorvastatin calcium (update).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:268bdfe9-ba51-4f27-bd16-dd127271693cEnglishSymplectic Elements at Oxford2007Blank, RHobbs, FZamorano, JGirerd, XThis review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering agent, and atorvastatin calcium, a statin with lipid-lowering antiatherosclerotic properties. Amlodipine and atorvastatin have been demonstrated in numerous clinical trials to be highly effective in lowering blood pressure and low-density lipoprotein cholesterol. Furthermore, both amlodipine and atorvastatin have been demonstrated to reduce cardiovascular events in a broad range of patients' in hypertensive patients with three concomitant cardiovascular risk factors but normal to mildly elevated cholesterol levels, amlodipine combined with atorvastatin demonstrated a reduction in cardiovascular events. The amlodipine/atorvastatin single pill has been shown to improve patients; achievement of national-guideline-recommended blood pressure and lipid target levels and exhibits a safety profile consistent with its parent compounds. The combination pill is now available in parts of Europe in formulations containing either 5 or 10 mg amlodipine and 10 mg atorvastatin. Amlodipine combined with atorvastatin has been demonstrated to reduce cardiovascular events in hypertensive patients at high cardiovascular risk, and the single-pill formulation has the potential to improve adherence and decrease prescription costs. These potential benefits are associated with important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events. |
| spellingShingle | Blank, R Hobbs, F Zamorano, J Girerd, X A single-pill combination of amlodipine besylate and atorvastatin calcium (update). |
| title | A single-pill combination of amlodipine besylate and atorvastatin calcium (update). |
| title_full | A single-pill combination of amlodipine besylate and atorvastatin calcium (update). |
| title_fullStr | A single-pill combination of amlodipine besylate and atorvastatin calcium (update). |
| title_full_unstemmed | A single-pill combination of amlodipine besylate and atorvastatin calcium (update). |
| title_short | A single-pill combination of amlodipine besylate and atorvastatin calcium (update). |
| title_sort | single pill combination of amlodipine besylate and atorvastatin calcium update |
| work_keys_str_mv | AT blankr asinglepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT hobbsf asinglepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT zamoranoj asinglepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT girerdx asinglepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT blankr singlepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT hobbsf singlepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT zamoranoj singlepillcombinationofamlodipinebesylateandatorvastatincalciumupdate AT girerdx singlepillcombinationofamlodipinebesylateandatorvastatincalciumupdate |